Hesperetin ameliorates diabetic nephropathy in rats by activating Nrf2/ARE/glyoxalase 1 pathway

• Published in: Biomedicine & pharmacotherapy Vol. 111; pp. 1166 - 1175
• Main Authors: Chen, Ya-Jing, Kong, Li, Tang, Zhuang-Zhuang, Zhang, Yu-Meng, Liu, Yue, Wang, Tao-Yun, Liu, Yao-Wu
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.03.2019
• Subjects: AGEs/RAGE axis; Animals; Carboxylic Ester Hydrolases - metabolism; Diabetes Mellitus, Experimental - chemically induced; Diabetes Mellitus, Experimental - complications; Diabetes Mellitus, Experimental - metabolism; Diabetic Nephropathies - drug therapy; Diabetic Nephropathies - etiology; Diabetic Nephropathies - metabolism; Diabetic nephropathy; Glutamate-Cysteine Ligase - metabolism; Glycation End Products, Advanced - metabolism; Glyoxalase 1; Hesperetin; Hesperidin - pharmacology; Inflammation - drug therapy; Inflammation - metabolism; Kidney - drug effects; Kidney - metabolism; Lactoylglutathione Lyase - metabolism; Male; NF-E2-Related Factor 2 - metabolism; Nrf2/ARE pathway; Protective Agents - pharmacology; Rats; Rats, Sprague-Dawley; Signal Transduction - drug effects; Streptozocin - pharmacology; Up-Regulation - drug effects; PBS; tBHQ; PAS; Hesperetin; Nrf2/ARE pathway; FN; Hst; DM; AGEs; DN; FBG; HO-1; γ-GCS; ARE; Glo-1; Nrf2; CMC-Na; STZ; Glyoxalase 1; CoIV; Diabetic nephropathy; BUN; AGEs/RAGE axis; GSH

[Display omitted] •Hesperetin could attenuate diabetic nephropathy.•Enhancement of glyoxalase 1 contributed to the beneficial effects.•Activation of Nrf2/ARE pathway was involved in glyoxalase 1 enhancement. Diabetic nephropathy (DN) is one of the most common diabetic complications, and alpha-carbon...